Edwards Lifesciences Corp (EW) Q4 2021 (USD): Adj. EPS 0.51 (exp. 0.55), Revenue 1.33bln (exp. 1.35bln).
SourceNewsquawk
SectionUS Equities
- FY22 guidance unchanged.
- Q1 total sales view between 1.27-1.35bln.
- Q1 adj. EPS of 0.54-0.62.
- Believe that opportunity to serve patients will nearly double between now and 2028.
Via PR Newswire